Skip to main content

Table 1 Clinicopathologic characteristics of colorectal cancer patients with liver metastases according to preoperative chemotherapy

From: Pathologic response after preoperative therapy predicts prognosis of Chinese colorectal cancer patients with liver metastases

Variable

Non-targeted therapy (n = 114)

Bev-combined therapy (n = 22)

Cet-combined therapy (n = 23)

Sex

 Man

72 (63.2)

14 (63.6)

15 (65.2)

 Woman

42 (36.8)

8 (36.4)

8 (34.8)

Primary tumor site

 Right side

18 (15.8)

7 (31.8)

4 (17.4)

 Left side

96 (84.2)

15 (68.2)

19 (82.6)

Primary tumor grade

 G1–2

84 (73.7)

18 (81.8)

16 (69.6)

 G3

30 (26.3)

4 (18.2)

7 (30.4)

Histological subtype

 Non-mucinous

102 (89.5)

20 (90.9)

20 (87.0)

 Mucinous

12 (10.5)

2 (9.1)

3 (13.0)

Primary tumor pT categorya

 pT1–2

11 (9.6)

1 (4.5)

2 (8.7)

 pT3–4

103 (90.4)

21 (95.5)

21 (91.3)

Primary tumor pN categorya

 pN0

57 (50.0)

12 (54.5)

8 (34.8)

 pN1-2

57 (50.0)

10 (45.5)

15 (65.2)

Preoperative CEA level

 ≤ 5 ng/mL

45 (39.5)

7 (31.8)

9 (39.1)

 > 5 ng/mL

69 (60.5)

15 (68.2)

14 (60.9)

Metastasis presentation

 Synchronous

92 (80.7)

18 (81.8)

16 (69.6)

 Metachronous

22 (19.3)

4 (18.2)

7 (30.4)

Number of metastases per patientb

3 (1–32)

3 (1–14)

6 (1–15)

Resection status of liver metastases

 R0

88 (77.2)

16 (72.7)

15 (65.2)

 R1–2

26 (22.8)

6 (27.2)

8 (34.7)

Cycles of preoperative chemotherapyb

4 (2–12)

6 (3–11)

4 (2–8)

Duration of preoperative chemotherapyc

 Short duration

58 (50.9)

8 (36.4)

11 (47.8)

 Long duration

56 (49.1)

14 (63.6)

12 (52.2)

Chemotherapy backbone

 Oxa-based

83 (72.8)

13 (59.1)

5 (21.7)

 Iri-based

26 (22.8)

9 (40.9)

17 (73.9)

 Oxa + Iri-based

3 (2.6)

0 (0.0)

1 (4.3)

 Fluoropyrimidine only

2 (1.8)

0 (0.0)

0 (0.0)

Postoperative chemotherapy

 Yes

70 (61.4)

15 (68.2)

14 (60.9)

 No

44 (38.6)

7 (31.8)

9 (39.1)

Responsed

 PR

39 (36.4)

14 (63.6)

17 (73.9)

 SD

47 (43.9)

8 (36.4)

6 (26.1)

 PD

21 (19.6)

0 (0.0)

0 (0.0)

TRGe

 1–2

32 (28.1)

8 (36.4)

4 (17.4)

 3

39 (34.2)

7 (31.8)

10 (43.5)

 4–5

43 (37.7)

7 (31.8)

9 (39.1)

  1. Bev bevacizumab, Cet cetuximab, CEA carcinoembryonic antigen, Oxa oxaliplatin, Iri irinotecan, PR partial response, SD stable disease, PD progression disease, TRG tumor regression grade
  2. a According to the Union for International Cancer Control (UICC) staging system (7th edition)
  3. b These data are presented as median followed by range in parentheses; others are presented as number of patients followed by percentages in parentheses
  4. c Short duration of preoperative chemotherapy: ≤ 4 cycles for 2-week regimens or ≤ 3 cycles for 3-week regimens; long duration of preoperative chemotherapy: > 4 cycles for 2-week regimens or > 3 cycles for 3-week regimens
  5. d Because the initial computed tomography or magnetic resonance imaging was performed in other hospitals, 7 of 114 patients who received preoperative chemotherapy without targeted therapy were not evaluable for radiologic response
  6. e TRG was evaluated based on the patient-related analysis
Back to article page

Cancer Communications

ISSN: 2523-3548

Contact us